{
    "root": "9cdaed50-275d-47ef-b4bd-c72f7cd8db9d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Buprenorphine",
    "value": "20250113",
    "ingredients": [
        {
            "name": "BUPRENORPHINE HYDROCHLORIDE",
            "code": "56W8MW3EN1"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "Buprenorphine Sublingual Tablets are indicated for the treatment of opioid dependence and are preferred for induction. Buprenorphine Sublingual Tablets should be used as part of a complete treatment plan to include counseling and psychosocial support.",
    "contraindications": "• Administer Buprenorphine Sublingual Tablets sublingually as a single daily dose. ( 2.1 ) • Strongly consider prescribing naloxone at the time Buprenorphine Sublingual Tablets are initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose ( 2.2 ) • To avoid precipitating withdrawal, induction with Buprenorphine Sublingual Tablets should be undertaken when objective and clear signs of withdrawal are evident. ( 2.3 ) • Buprenorphine and naloxone sublingual film or buprenorphine and naloxone sublingual tablets are generally initiated after two days of Buprenorphine Sublingual Tablet titration. ( 2.4 ) • Administer Buprenorphine Sublingual Tablets as directed in the Full Prescribing Information. ( 2.3 , 2.4 , 2.5 ) • Buprenorphine Sublingual Tablets must be administered whole.  Do not cut, chew, or swallow Buprenorphine Sublingual Tablets. ( 2.5 ) • When discontinuing treatment, gradually taper to avoid signs and symptoms of withdrawal. ( 2.9 )",
    "warningsAndPrecautions": "Buprenorphine Sublingual Tablets \n                  \n                  \n                     2 mg, supplied as white, flat faced, beveled-edge tablets with product identification \"54” over “775\" on one side and plain on the other side. \n                  \n                  NDC 0054-0176-13: Bottle of 30 Sublingual Tablets\n                  \n                     8 mg, supplied as white, flat faced, beveled-edge tablets with product identification \"54” over “411\" on one side and plain on the other side. \n                  \n                  NDC 0054-0177-13: Bottle of 30 Sublingual Tablets\n                  \n                     Storage\n                  \n                  Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]\n                  Dispense in a tight, light-resistant container as defined in USP.\n                  Store Buprenorphine Sublingual Tablets securely and dispose of properly [see Patient Counseling Information (17)].",
    "adverseReactions": "Buprenorphine Sublingual Tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings and Precautions (5.9)]."
}